(Q33338669)

English

Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

transitional cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

H Gurney

6

0 references

author name string

C Shannon

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

C Crombie

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

A Brooks

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

H Lau

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

M Drummond

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 July 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

947-952

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin-based chemotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011186104428

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1011186104428

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33338669&oldid=1951016338"